Effector Therapeutics

OverviewSuggest Edit

Effector Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.

TypePrivate
Founded2012
HQSan Diego, US
Websiteeffector.com

Latest Updates

Employees (est.) (Sept 2020)28(+8%)
Cybersecurity ratingAMore

Key People/Management at Effector Therapeutics

Larry Lasky

Larry Lasky

Director
Simeon George

Simeon George

Director
Steve Worland

Steve Worland

President and Chief Executive Officer, Director
Premal Patel

Premal Patel

Chief Medical Officer
Denis Patrick

Denis Patrick

Director
Mark Densel

Mark Densel

Vice President, Development Operations
Show more

Effector Therapeutics Office Locations

Effector Therapeutics has an office in San Diego
San Diego, US (HQ)
11180 Roselle St
Show all (1)

Effector Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2012

Effector Therapeutics total Funding

$101 m

Effector Therapeutics latest funding size

$16 m

Time since last funding

5 years ago

Effector Therapeutics investors

Effector Therapeutics's latest funding round in February 2016 was reported to be $16 m. In total, Effector Therapeutics has raised $101 m
Show all financial metrics

Effector Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Effector Therapeutics Online and Social Media Presence

Embed Graph

Effector Therapeutics Blogs

Research Published in Nature Medicine Demonstrates the Immunological Effects of Tomivosertib, Including Inhibiting Production of Checkpoint Protein PD-L1 and Increasing T Cell Infiltration into Tumors

SAN DIEGO, January 14, 2019 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced publication in the peer reviewed journal Nature Medicine of preclinical research demonstrating that tomivosertib (eFT508), th…

eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)

SAN DIEGO, CA — December 11, 2018 — eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it has dosed the first patient in a Phase 2 trial of tomivosertib (eFT508) in men with advanced castra…

Data Presented at AACR Special Conference on PI3K/mTOR Signaling Demonstrates Potential of eFFECTOR’s eIF4E Inhibitors in Cancer

SAN DIEGO, December 3, 2018 — eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it presented data on Sunday, December 2 at the AACR Special Conference on PI3K/mTOR Signaling demonstrating …

eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR’s Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer

SAN DIEGO, October 16, 2018 - eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada)

eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone

SAN DIEGO, July 27, 2018 -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company’s oral, small molecule in…
Show more

Effector Therapeutics Frequently Asked Questions

  • When was Effector Therapeutics founded?

    Effector Therapeutics was founded in 2012.

  • Who are Effector Therapeutics key executives?

    Effector Therapeutics's key executives are Larry Lasky, Simeon George and Steve Worland.

  • How many employees does Effector Therapeutics have?

    Effector Therapeutics has 28 employees.

  • Who are Effector Therapeutics competitors?

    Competitors of Effector Therapeutics include Aptevo Therapeutics, Geron and Aeglea Biotherapeutics.

  • Where is Effector Therapeutics headquarters?

    Effector Therapeutics headquarters is located at 11180 Roselle St, San Diego.

  • Where are Effector Therapeutics offices?

    Effector Therapeutics has an office in San Diego.

  • How many offices does Effector Therapeutics have?

    Effector Therapeutics has 1 office.